(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 255.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
X4 Pharmaceuticals's revenue in 2025 is $2,557,000.On average, 5 Wall Street analysts forecast XFOR's revenue for 2025 to be $2,790,059,733, with the lowest XFOR revenue forecast at $1,701,891,285, and the highest XFOR revenue forecast at $6,013,928,081. On average, 5 Wall Street analysts forecast XFOR's revenue for 2026 to be $4,955,976,886, with the lowest XFOR revenue forecast at $2,855,009,461, and the highest XFOR revenue forecast at $7,128,840,535.
In 2027, XFOR is forecast to generate $23,185,663,820 in revenue, with the lowest revenue forecast at $7,019,433,238 and the highest revenue forecast at $54,998,874,479.